Chemistry:Lulizumab pegol
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | glycoprotein CD28 |
| Clinical data | |
| Other names | BMS-931699 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C552H859N149O164S4 |
| Molar mass | 12335.06 g·mol−1 |
Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody developed by Bristol-Myers Squibb for the treatment of autoimmune diseases[2] such as cutaneous lupus erythematosus.[3]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111". WHO Drug Information 28 (2). 2014. https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol"]. American Medical Association. http://www.ama-assn.org/resources/doc/usan/x-pub/lulizumab-pegol.pdf.
- ↑ "Advances in the treatment of cutaneous lupus erythematosus". Lupus 25 (8): 830–837. July 2016. doi:10.1177/0961203316641771. PMID 27252259.
 |  |
